Targeting PI3K/Akt/mTOR Signaling in Cancer

By C. Porta, C. Paglino, A. Mosca. Frontiers in Oncology, 2014

1,442 citations recorded by the source corpus.

The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling pathways are two pathways crucial to many aspects of cell growth and survival, in physiological as well as in pathological conditions (e.g., cancer). Indeed, they are so interconnected that, in a certain sense, they could be regarded as a single, unique pathway. In this paper, after a general overview of the biological significance and the main components of these pathways, we address the present status of the development of specific PI3K, Akt, and mTOR inhibitors, from already registered medicines to novel compounds that are just leaving the laboratory bench.

Subfields: Molecular Biology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/719e44a0ec152b8f2a205d3c111784d3aa670a92

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Bin Li
2. Kui-Sheng Chen
3. Miao-miao Sun
4. Jing Yang
5. Yan He
6. Guo Geng Zhang
7. W. Xu

Citations in the corpus

• Targeting PI3K/Akt signal transduction for cancer therapy (2021, background): “Many growth factors and their receptors, such as VEGF and VEGFR, act as positive regulators to transmit signals to mTOR through the PI3K/Akt pathway.(80) Under normal conditions, PI3K activity is at a basal level.”